Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor: early-phase trial registry
104 of 197 indexed Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #53 of 28,707 conditions by registered trial count.
197 US clinical trials · 104 currently recruiting · #53 of 28,707 conditions by registered trial count
Solid Tumor: 197 US clinical trials tracked, 104 recruiting.
Solid Tumor is the subject of 197 registered US clinical trials on ClinicalTrials.gov, 104 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 165 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition solid-tumor
OPEN 104 | RECR 53% | LATE 4 | EARLY 165 | RANK #53 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Metastatic Breast Cancer (53% recruiting · 140 trials)
Solid Tumor lists 104 open slots (53% of 197 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor is recruiting above its size-band peers.
104 of 197 indexed trials (52.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumor trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 11 of 197 trials (5.6%). 149 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor enrolment sits around 80 participants.
Median target enrolment is 80 among the 197 trials that report a genuine target (sentinel values excluded). 108 of those (54.8%) plan for fewer than 100 participants.
-
Solid Tumor research is mostly interventional.
179 interventional and 18 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
197 total, page 1 of 4
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
National Cancer Institute (NCI)
NCT03739827
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Children's Oncology Group
NCT00736749
Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
Memorial Sloan Kettering Cancer Center
NCT05390827
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma
NCT05382559
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines
NCT05919264
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Sanofi
NCT05584670
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Biohaven Therapeutics
NCT06384807
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech
NCT06619587
The Intersection of Oncology Care and Worker Well-Being
University of Colorado, Denver
NCT05250284
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme
NCT02332668
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma
NCT07094204
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05245500
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
NCT05557045
A Study of PYX-201 in Advanced Solid Tumors
Pyxis Oncology
NCT05720117
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
Psychotherapy Intervention for Latinos With Adv Cancer
Memorial Sloan Kettering Cancer Center
NCT04537936
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics
NCT06234423
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Memorial Sloan Kettering Cancer Center
NCT04942717
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co.
NCT06259552
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
NCT04084067
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Novartis Pharmaceuticals
NCT04939610
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06305247
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Chugai Pharmaceutical
NCT05907980
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
NCT05981703
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04165772
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Oxford BioTherapeutics
NCT04064359
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics
NCT07300150
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics
NCT06810544
Psychotherapy Intervention for Latinos With Advanced Cancer
Memorial Sloan Kettering Cancer Center
NCT04015609
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
STORM Therapeutics
NCT06975293
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai
NCT04300556
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
NCT04794699
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Yuhan Corporation
NCT06616766
Implementation of an Oral Chemotherapy Adherence Intervention
UNC Lineberger Comprehensive Cancer Center
NCT06989489
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals
NCT06603844
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05585684
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen
NCT05989724
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Pierre Fabre Medicament
NCT06669117
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
NCT04516447
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co.
NCT05784688
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
NCT06576037
DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
Memorial Sloan Kettering Cancer Center
NCT07225088
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT05480904
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
Medical College of Wisconsin
NCT05301101
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 150 |
| Phase 2 | 15 |
| Phase 3 | 1 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor page
197 registered trials, 104 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 104 Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor condition card totals 197 registered trials; most-linked intervention Nivolumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.